Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis.
Aged
B7-H1 Antigen
/ antagonists & inhibitors
Carcinoma, Non-Small-Cell Lung
/ genetics
Female
Humans
Lung Neoplasms
/ genetics
Male
Middle Aged
Mutation
/ genetics
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Proto-Oncogene Proteins p21(ras)
/ genetics
Retrospective Studies
Survival Analysis
Treatment Outcome
KRAS
NSCLC
anti-PDI/PD-L1 therapy
immunotherapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
01
11
2019
revised:
14
11
2019
accepted:
18
11
2019
entrez:
2
1
2020
pubmed:
2
1
2020
medline:
10
1
2020
Statut:
ppublish
Résumé
The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS patients. Among 328 consecutive KRAS KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLC patients, independently of KRAS status.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The role of anti-PD1/PD-L1 therapy (IO) in NSCLC harboring driver mutations is questionable. This study aimed to examine the efficacy of IO in patients with non-small cell lung cancer (NSCLC) with a KRAS mutation (KRAS
PATIENTS AND METHODS
METHODS
We retrospectively identified NSCLC patients harboring KRAS mutation treated with IO in our Institution. We analyzed the results in comparison to non-KRAS patients.
RESULTS
RESULTS
Among 328 consecutive KRAS
CONCLUSION
CONCLUSIONS
KRAS mutations seem to be irrelevant for selecting patients for IO that could be therefore considered an effective therapy for NSCLC patients, independently of KRAS status.
Identifiants
pubmed: 31892597
pii: 40/1/427
doi: 10.21873/anticanres.13970
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
KRAS protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-433Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.